Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor that selectively restraining the autophosphorylation of receptors such as VEGFR-2, Kit, and PDGFR-β in renal cell carcinoma (46). This evidence concerns the gene NTRK1 and hereditary clear cell renal cell carcinoma.